A 5‐year‐old boy with Kawasaki disease shock syndrome, myocarditis and macrophage activation syndrome
暂无分享,去创建一个
Surjit Singh | K. Arora | R. Pilania | P. Vignesh | D. Suri | Aman Gupta
[1] Surjit Singh,et al. An Update on Treatment of Kawasaki Disease , 2019, Current Treatment Options in Rheumatology.
[2] M. Alphonse,et al. Kawasaki Disease-Associated Cytokine Storm Syndrome , 2019, Cytokine Storm Syndrome.
[3] Surjit Singh,et al. Controversies in diagnosis and management of Kawasaki disease , 2018, World journal of clinical pediatrics.
[4] D. Burgner,et al. Treatment Options for Resistant Kawasaki Disease , 2018, Pediatric Drugs.
[5] K. L. Borjas-Aguilar,et al. Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review , 2017, Journal of pediatric hematology/oncology.
[6] B. McCrindle,et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.
[7] C. Wouters,et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis , 2016, Annals of the rheumatic diseases.
[8] A. Rawat,et al. Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease , 2016, Rheumatology International.
[9] L. Monasta,et al. Describing Kawasaki shock syndrome: results from a retrospective study and literature review , 2016, Clinical Rheumatology.
[10] J. Kanegaye,et al. Recognition of a Kawasaki Disease Shock Syndrome , 2009, Pediatrics.